Literature DB >> 18408080

VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity.

C Pieh1, H Agostini, C Buschbeck, M Krüger, J Schulte-Mönting, U Zirrgiebel, J Drevs, W A Lagrèze.   

Abstract

AIM: To study prospectively the plasma levels of vascular endothelial growth factor (VEGF-A), its soluble receptors sVEGFR-1, sVEGFR-2 and soluble Tie2 in premature infants. To identify their changes related to the onset of retinopathy of prematurity (ROP).
METHODS: Blood samples of 63 preterm infants born at a postmenstrual age (PMA) of 23-32 weeks were obtained between 5 days and 15 weeks after birth. 42 infants had no ROP, two had stage 1, nine stage 2 and 10 stage 3. Of these, four infants were treated with retinal photocoagulation. VEGF-A, sVEGFR-1, sVEGFR-2, and sTie2 were measured in the plasma with a sandwich enzyme immunoassay using factor-specific monoclonal mouse antibodies. The time course of concentrations plotted by kernel smoothing in infants with and without ROP were compared and a paired subgroup with analysis of variance was analysed.
RESULTS: ROP patients had raised plasma levels of sVEGFR-2 and sTie2 compared with premature infants without ROP. VEGF-A and sVEGFR-1 levels were similar in both groups. Analysis of a subgroup with pairs of measurements, one before 32 weeks and one after 36 weeks, showed a significant increase in sTie2 after 36 weeks of PMA independent of ROP (p = 0.03).
CONCLUSION: This is the first study to measure plasma levels of angiogenic factors in ROP. Similar VEGF-A plasma levels in infants with and without ROP suggest that pathogenic retinal angiogenesis in ROP is mainly driven by local VEGF-A synthesis. Elevated plasma levels in active ROP were observed for sVEGFR-2 and sTie2. These increases have yet to be confirmed as predictive values for ROP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408080     DOI: 10.1136/bjo.2007.128371

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

Review 1.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

2.  [Pharmacological treatment for retinopathy of prematurity].

Authors:  A Stahl; H Agostini; C Jandeck; W Lagrèze
Journal:  Ophthalmologe       Date:  2011-08       Impact factor: 1.059

3.  Serum fructosamine and retinopathy of prematurity.

Authors:  Senol Bozdag; Serife Suna Oguz; Tulin Gokmen; Zuhal Tunay; Levent Tok; Nurdan Uras; Omer Erdeve; Ugur Dilmen
Journal:  Indian J Pediatr       Date:  2011-07-06       Impact factor: 1.967

4.  Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity.

Authors:  Luz Consuelo Zepeda-Romero; Miguel Vazquez-Membrillo; Elva Adan-Castro; Francisco Gomez-Aguayo; Jose Alfonso Gutierrez-Padilla; Eusebio Angulo-Castellanos; Juan Carlos Barrera de Leon; Cesareo Gonzalez-Bernal; Manuel Alejandro Quezada-Chalita; Alonso Meza-Anguiano; Nundehui Diaz-Lezama; Gonzalo Martinez de la Escalera; Jakob Triebel; Carmen Clapp
Journal:  Pediatr Res       Date:  2016-11-14       Impact factor: 3.756

5.  Serum concentrations of vascular endothelial growth factor in relation to retinopathy of prematurity.

Authors:  Gunnel Hellgren; Chatarina Löfqvist; Anna-Lena Hård; Ingrid Hansen-Pupp; Magnus Gram; David Ley; Lois E Smith; Ann Hellström
Journal:  Pediatr Res       Date:  2015-09-15       Impact factor: 3.756

Review 6.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

7.  Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491.

Authors:  Luca Filippi; Giacomo Cavallaro; Patrizio Fiorini; Marta Daniotti; Valentina Benedetti; Gloria Cristofori; Gabriella Araimo; Luca Ramenghi; Agostino La Torre; Pina Fortunato; Liliana Pollazzi; Giancarlo la Marca; Sabrina Malvagia; Paola Bagnoli; Chiara Ristori; Massimo Dal Monte; Anna Rita Bilia; Benedetta Isacchi; Sandra Furlanetto; Francesca Tinelli; Giovanni Cioni; Gianpaolo Donzelli; Silvia Osnaghi; Fabio Mosca
Journal:  BMC Pediatr       Date:  2010-11-18       Impact factor: 2.125

8.  An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression.

Authors:  Christopher M Schafer; Jami M Gurley; Katarzyna Kurylowicz; Prisca K Lin; Wen Chen; Michael H Elliott; George E Davis; Faizah Bhatti; Courtney T Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

9.  Brain-derived neurotrophic factor in infants <32 weeks gestational age: correlation with antenatal factors and postnatal outcomes.

Authors:  Rakesh Rao; Charles B Mashburn; Jingnan Mao; Nitin Wadhwa; George M Smith; Nirmala S Desai
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

10.  Analysis of circulating hem-endothelial marker RNA levels in preterm infants.

Authors:  Tzipora Strauss; Sally Metsuyanim; Itai Pessach; Irit Shuchan-Eisen; Jacob Kuint; Benjamin Dekel
Journal:  BMC Pediatr       Date:  2009-06-25       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.